Index
1 Multiple Sclerosis (MS) Drugs Market Overview
1.1 Product Overview and Scope of Multiple Sclerosis (MS) Drugs
1.2 Multiple Sclerosis (MS) Drugs Segment by Type
1.2.1 Global Multiple Sclerosis (MS) Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Copaxone (Glatiramer Acetate, Copolymer 1)
1.2.3 Novantrone (Mitoxantrone)
1.2.4 Gilenya (Fingolimod, Fty720)
1.2.5 Aubagio (Teriflunomide)
1.2.6 Tecfidera (Dimethyl Fumarate)
1.2.7 Firategrast (Sb683699, T-0047)
1.2.8 Siponimod (Baf312)
1.2.9 Others
1.3 Multiple Sclerosis (MS) Drugs Segment by Application
1.3.1 Global Multiple Sclerosis (MS) Drugs Market Value by Application: (2024-2030)
1.3.2 RRMS
1.3.3 SPMS
1.3.4 PPMS
1.3.5 PRMS
1.4 Global Multiple Sclerosis (MS) Drugs Market Size Estimates and Forecasts
1.4.1 Global Multiple Sclerosis (MS) Drugs Revenue 2019-2030
1.4.2 Global Multiple Sclerosis (MS) Drugs Sales 2019-2030
1.4.3 Global Multiple Sclerosis (MS) Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Multiple Sclerosis (MS) Drugs Market Competition by Manufacturers
2.1 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Multiple Sclerosis (MS) Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Multiple Sclerosis (MS) Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Multiple Sclerosis (MS) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Multiple Sclerosis (MS) Drugs, Product Type & Application
2.7 Multiple Sclerosis (MS) Drugs Market Competitive Situation and Trends
2.7.1 Multiple Sclerosis (MS) Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Multiple Sclerosis (MS) Drugs Players Market Share by Revenue
2.7.3 Global Multiple Sclerosis (MS) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Multiple Sclerosis (MS) Drugs Retrospective Market Scenario by Region
3.1 Global Multiple Sclerosis (MS) Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Multiple Sclerosis (MS) Drugs Global Multiple Sclerosis (MS) Drugs Sales by Region: 2019-2030
3.2.1 Global Multiple Sclerosis (MS) Drugs Sales by Region: 2019-2024
3.2.2 Global Multiple Sclerosis (MS) Drugs Sales by Region: 2025-2030
3.3 Global Multiple Sclerosis (MS) Drugs Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2019-2030
3.3.1 Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2019-2024
3.3.2 Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2025-2030
3.4 North America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
3.4.1 North America Multiple Sclerosis (MS) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Multiple Sclerosis (MS) Drugs Sales by Country (2019-2030)
3.4.3 North America Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
3.5.1 Europe Multiple Sclerosis (MS) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Multiple Sclerosis (MS) Drugs Sales by Country (2019-2030)
3.5.3 Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Multiple Sclerosis (MS) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
3.7.1 Latin America Multiple Sclerosis (MS) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2019-2030)
3.7.3 Latin America Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Multiple Sclerosis (MS) Drugs Sales by Type (2019-2030)
4.1.1 Global Multiple Sclerosis (MS) Drugs Sales by Type (2019-2024)
4.1.2 Global Multiple Sclerosis (MS) Drugs Sales by Type (2025-2030)
4.1.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2019-2030)
4.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2019-2030)
4.2.1 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2019-2024)
4.2.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2025-2030)
4.2.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Multiple Sclerosis (MS) Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Multiple Sclerosis (MS) Drugs Sales by Application (2019-2030)
5.1.1 Global Multiple Sclerosis (MS) Drugs Sales by Application (2019-2024)
5.1.2 Global Multiple Sclerosis (MS) Drugs Sales by Application (2025-2030)
5.1.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2019-2030)
5.2 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2019-2030)
5.2.1 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2019-2024)
5.2.2 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2025-2030)
5.2.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Multiple Sclerosis (MS) Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bayer AG
6.1.1 Bayer AG Corporation Information
6.1.2 Bayer AG Description and Business Overview
6.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolio
6.1.5 Bayer AG Recent Developments/Updates
6.2 Bayhill Therapeutics
6.2.1 Bayhill Therapeutics Corporation Information
6.2.2 Bayhill Therapeutics Description and Business Overview
6.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
6.2.5 Bayhill Therapeutics Recent Developments/Updates
6.3 Biogen Idec
6.3.1 Biogen Idec Corporation Information
6.3.2 Biogen Idec Description and Business Overview
6.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolio
6.3.5 Biogen Idec Recent Developments/Updates
6.4 Cinnagen
6.4.1 Cinnagen Corporation Information
6.4.2 Cinnagen Description and Business Overview
6.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolio
6.4.5 Cinnagen Recent Developments/Updates
6.5 Daiichi Sankyo
6.5.1 Daiichi Sankyo Corporation Information
6.5.2 Daiichi Sankyo Description and Business Overview
6.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolio
6.5.5 Daiichi Sankyo Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 Fast Forward Llc
6.6.1 Fast Forward Llc Corporation Information
6.6.2 Fast Forward Llc Description and Business Overview
6.6.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolio
6.7.5 Fast Forward Llc Recent Developments/Updates
6.8 Antisense Therapeutics
6.8.1 Antisense Therapeutics Corporation Information
6.8.2 Antisense Therapeutics Description and Business Overview
6.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
6.8.5 Antisense Therapeutics Recent Developments/Updates
6.9 Apitope
6.9.1 Apitope Corporation Information
6.9.2 Apitope Description and Business Overview
6.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Apitope Multiple Sclerosis (MS) Drugs Product Portfolio
6.9.5 Apitope Recent Developments/Updates
6.10 Five Prime Therapeutics
6.10.1 Five Prime Therapeutics Corporation Information
6.10.2 Five Prime Therapeutics Description and Business Overview
6.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
6.10.5 Five Prime Therapeutics Recent Developments/Updates
6.11 Genmab
6.11.1 Genmab Corporation Information
6.11.2 Genmab Multiple Sclerosis (MS) Drugs Description and Business Overview
6.11.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Genmab Multiple Sclerosis (MS) Drugs Product Portfolio
6.11.5 Genmab Recent Developments/Updates
6.12 Artielle Immunotherapeutics
6.12.1 Artielle Immunotherapeutics Corporation Information
6.12.2 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Description and Business Overview
6.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
6.12.5 Artielle Immunotherapeutics Recent Developments/Updates
6.13 Genzyme
6.13.1 Genzyme Corporation Information
6.13.2 Genzyme Multiple Sclerosis (MS) Drugs Description and Business Overview
6.13.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Genzyme Multiple Sclerosis (MS) Drugs Product Portfolio
6.13.5 Genzyme Recent Developments/Updates
6.14 Glaxosmithkline
6.14.1 Glaxosmithkline Corporation Information
6.14.2 Glaxosmithkline Multiple Sclerosis (MS) Drugs Description and Business Overview
6.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolio
6.14.5 Glaxosmithkline Recent Developments/Updates
6.15 Gw Pharmaceuticals
6.15.1 Gw Pharmaceuticals Corporation Information
6.15.2 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Description and Business Overview
6.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolio
6.15.5 Gw Pharmaceuticals Recent Developments/Updates
6.16 Innate Immunotherapeutics
6.16.1 Innate Immunotherapeutics Corporation Information
6.16.2 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Description and Business Overview
6.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
6.16.5 Innate Immunotherapeutics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Multiple Sclerosis (MS) Drugs Industry Chain Analysis
7.2 Multiple Sclerosis (MS) Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Multiple Sclerosis (MS) Drugs Production Mode & Process
7.4 Multiple Sclerosis (MS) Drugs Sales and Marketing
7.4.1 Multiple Sclerosis (MS) Drugs Sales Channels
7.4.2 Multiple Sclerosis (MS) Drugs Distributors
7.5 Multiple Sclerosis (MS) Drugs Customers
8 Multiple Sclerosis (MS) Drugs Market Dynamics
8.1 Multiple Sclerosis (MS) Drugs Industry Trends
8.2 Multiple Sclerosis (MS) Drugs Market Drivers
8.3 Multiple Sclerosis (MS) Drugs Market Challenges
8.4 Multiple Sclerosis (MS) Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer